From mice to men and back: An assessment of preclinical model systems for the study of lung cancers

Journal of Thoracic Oncology

Volumn 11, Issue 3, 2016, Pages 287-299

  Gazdar, Adi F ^a   Hirsch, Fred R ^b   Minna, John D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Cell lines; Cell Lines; Genetically Engineered Mouse Models; Lung Cancer; Neuroendocrine Carcinomas; Non Small Cell Lung Cancer; Patient Derived Xenografts; Preclinical Models; Small Cell Lung Cancer

Indexed keywords

CANCER RESEARCH; DISEASE MODEL; GENETICALLY ENGINEERED MOUSE STRAIN; HISTOPATHOLOGY; HUMAN; LUNG CANCER; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMALL CELL LUNG CANCER; TUMOR CELL LINE; TUMOR XENOGRAFT; ANIMAL; LUNG TUMOR; MOUSE; PATHOLOGY; SCID MOUSE; TRANSGENIC MOUSE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; MICE, TRANSGENIC;

EID: 84962522570     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.10.009     Document Type: Review

References (72)

1. Kellar A, Egan C, Morris D. Preclinical murine models for lung cancer: Clinical trial applications. Biomed Res Int. 2015; 2015: 621324.
2. Gazdar AF, Girard L, Lockwood WW, et al. Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst. 2010; 102: 1310-1321.
3. Gazdar AF, Gao B, Minna JD. Lung cancer cell lines: useless artifacts or invaluable tools for medical science? Lung Cancer. 2010; 68: 309-318.
4. Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013; 105: 452-458.
5. Ince TA, Sousa AD, Jones MA, et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun. 2015; 6: 7419.
6. Oboshi S, Tsugawa S, Seido T, et al. A new floating cell line derived from human pulmonary carcinoma of oat cell type. Gan. 1971; 62: 505-514.
7. Scherer WF, Syverton JT, Gey GO. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med. 1953; 97: 695-710.
8. Reed MV, Gey GO. Cultivation of normal and malignant human lung tissue. I. The establishment of three adenocarcinoma cell strains. Lab Invest. 1962; 11: 638-652.
9. Blanco R, Iwakawa R, Tang M, et al. A gene-Alteration profile of human lung cancer cell lines. Hum Mutat. 2009; 30: 1199-1206.
10. Pleasance ED, Stephens PJ, OMeara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010; 463: 184-190.
11. Freedman LP, Gibson MC, Ethier SP, et al. Reproducibility: changing the policies and culture of cell line authentication. Nat Methods. 2015; 12: 493-497.
12. Giard DJ, Aaronson SA, Todaro GJ, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973; 51: 1417-1423.
13. Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One. 2009; 4: e4576.
14. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011; 71: 6051-6060.
15. Pettengill OS, Sorenson GD, Wurster-Hill DH, et al. Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung. Cancer. 1980; 45: 906-918.
16. Gazdar AF, Carney DN, Russell EK, et al. Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res. 1980; 40: 3502-3507.
17. Phelps RM, Johnson BE, Ihde DC, et al. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl. 1996; 24: 32-91.
18. Gazdar AF, Carney DN, Nau MM, et al. Characterization of variant subclasses of cell lines derived fromsmall cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 1985; 45: 2924-2930.
19. Rosfjord E, Lucas J, Li G, et al. Advances in patientderived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol. 2014; 91: 135-143.
20. Isobe T, Onn A, Morgensztern D, et al. Evaluation of novel orthotopic nude mouse models for human smallcell lung cancer. J Thorac Oncol. 2013; 8: 140-146.
21. Gazdar AF, Carney DN, Sims HL, et al. Heterotransplantation of small-cell carcinoma of the lung into nude mice: comparison of intracranial and subcutaneous routes. Int J Cancer. 1981; 28: 777-783.
22. Hao C, Wang L, Peng S, et al. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015; 357: 179-185.
23. Stewart EL, Mascaux C, Pham NA, et al. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFRmutant lung adenocarcinoma. J Clin Oncol. 2015; 33: 2472-2480.
24. Gandara DR, Lara Jr PN, Mack PC. Patient-derived xenografts for investigation of acquired resistance in oncogene-driven cancers: building a better mousetrap. J Clin Oncol. 2015; 33: 2839-2840.
25. Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 2014; 4: 998-1013.
26. Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 2014; 344: 1-12.
27. Zhang YA, Maitra A, Hsieh JT, et al. Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther. 2011; 12: 617-628.
28. Vikis HG, Rymaszewski AL, Tichelaar JW. Mouse models of chemically-induced lung carcinogenesis. Front Biosci (Elite Ed). 2013; 5: 939-946.
29. Kwon MC, Berns A. Mouse models for lung cancer. Mol Oncol. 2013; 7: 165-177.
30. Politi K, Pao W. How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol. 2011; 29: 2273-2281.
31. Farago AF, Snyder EL, Jacks T. SnapShot: lung cancer models. Cell. 2012; 149: 246-246.e241.
32. Taguchi A, Politi K, Pitteri SJ, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 2011; 20: 289-299.
33. Travis W, Brambilla E, Noguchi M, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2009; 4: 244-285.
34. Skoulidis F, Byers LA, Diao L, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015; 5: 860-877.
35. Westcott PM, Halliwill KD, To MD, et al. The mutational landscapes of genetic and chemical models of Krasdriven lung cancer. Nature. 2015; 517: 489-492.
36. Meuwissen R, Linn SC, Linnoila RI, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003; 4: 181-189.
37. Gazdar AF, Savage TK, Johnson JE, et al. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol. 2015; 10: 553-564.
38. McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell. 2014; 156: 1298-1311.
39. You MS, Rouggly LC, You M, et al. Mouse models of lung squamous cell carcinomas. Cancer Metastasis Rev. 2013; 32: 77-82.
40. Xiao Z, Jiang Q, Willette-Brown J, et al. The pivotal role of IKKalpha in the development of spontaneous lung squamous cell carcinomas. Cancer Cell. 2013; 23: 527-540.
41. Xu C, Fillmore CM, Koyama S, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PDL1 expression. Cancer Cell. 2014; 25: 590-604.
42. Liu X, Ory V, Chapman S, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol. 2012; 180: 599-607.
43. Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in smallcell lung cancer. Nat Med. 2014; 20: 897-903.
44. Breslin S, ODriscoll L. Three-dimensional cell culture: The missing link in drug discovery. Drug Discov Today. 2013; 18: 240-249.
45. Vidi PA, Bissell MJ, Lelievre SA. Three-dimensional culture of human breast epithelial cells: The how and the why. Methods Mol Biol. 2013; 945: 193-219.
46. Lovitt CJ, Shelper TB, Avery VM. Advanced cell culture techniques for cancer drug discovery. Biology (Basel). 2014; 3: 345-367.
47. Endo H, Okami J, Okuyama H, et al. Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation. J Thorac Oncol. 2013; 8: 131-139.
48. Sullivan JP, Spinola M, Dodge M, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010; 70: 9937-9948.
49. Ramirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 2004; 64: 9027-9034.
50. Sato M, Larsen JE, Lee W, et al. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res. 2013; 11: 638-650.
51. Kim HS, Mendiratta S, Kim J, et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 2013; 155: 552-566.
52. Singh P, Schimenti JC, Bolcun-Filas E. A mouse geneticists practical guide to CRISPR applications. Genetics. 2015; 199: 1-15.
53. Sanchez-Rivera FJ, Jacks T. Applications of the CRISPRCas9 system in cancer biology. Nature Rev Cancer. 2015; 15: 387-395.
54. Chen S, Sanjana NE, Zheng K, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015; 160: 1246-1260.
55. Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature. 2007; 446: 815-819.
56. Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009; 119: 3000-3010.
57. Whang-Peng J, Kao-Shan CS, Lee EC, et al. Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science. 1982; 215: 181-182.
58. Whang-Peng J, Knutsen T, Gazdar A, et al. Nonrandom structural and numerical chromosome changes in non-small-cell lung cancer. Genes Chromosomes Cancer. 1991; 3: 168-188.
59. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001; 93: 691-699.
60. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 2002; 21: 6915-6935.
61. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000; 25: 315-319.
62. Harbour JW, Lai SL, Whang-Peng J, et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988; 241: 353-357.
63. Takahashi T, Nau MM, Chiba I, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science. 1989; 246: 491-494.
64. Little CD, Nau MM, Carney DN, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature. 1983; 306: 194-196.
65. Nau MM, Brooks BJ, Battey J, et al. L-myc, a new mycrelated gene amplified and expressed in human small cell lung cancer. Nature. 1985; 318: 69-73.
66. Johnson BE, Makuch RW, Simmons AD, et al. myc family DNA amplification in small cell lung cancer patients tumors and corresponding cell lines. Cancer Res. 1988; 48: 5163-5166.
67. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005; 65: 1642-1646.
68. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
69. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304: 554.
70. Vikis H, Sato M, James M, et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res. 2007; 67: 4665-4670.
71. Zhou W, Ercan D, Janne PA, et al. Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorg Med Chem Lett. 2011; 21: 638-643.
72. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011; 1: 78-89.